Syros Pharmaceuticals, Inc.
SYRSHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | |
|---|---|---|---|---|---|---|
| Revenue | $9.9M | $14.9M | $23.5M | $15.1M | $2.0M | $2.0M |
| Operating income | −$129.0M | −$135.9M | −$99.4M | −$82.3M | −$77.7M | −$64.3M |
| Net income | −$164.6M | −$94.7M | −$86.6M | −$84.0M | −$75.4M | −$62.3M |
| Total assets | $168.2M | $244.5M | $182.9M | $213.3M | $150.0M | $106.8M |
| Total liabilities | — | — | — | — | — | — |
| Equity | $16.7M | $127.7M | $85.2M | $90.6M | $79.2M | $78.6M |
| EPS (diluted) | $-5.81 | $-7.49 | $-13.84 | $-18.20 | — | — |
| Shares out. | 20.3M | 62.1M | 61.6M | 43.4M | 32.8M | 32.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- −1298.2%
- Net margin
- −1656.3%
- Return on equity
- −987.7%
- Return on assets
- −97.9%
- Return on capital (ROCE)
- −98.1%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $0.82
- Revenue growth (YoY)
- −33.2%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Accruals / assets
- −32.6%clean
- Piotroski F-Score
- 2/8weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 4 warning● 1 good- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Samsara Biocapital, L.P.Activist (13D)Mar 27, 2025
- Deep Track Capital, LpPassive (13G)Feb 14, 2025
- Avidity Partners Management LpPassive (13G)Feb 14, 2025
- Point72 Asset Management, L.P.Passive (13G)Feb 14, 2025
- Invus Global Management, LlcPassive (13G)Feb 12, 2025
- Adage Capital Partners Gp, L.L.C.Passive (13G)Feb 12, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Simonian Nancy ADirector | Dec 2, 2024 | Sell | 37,070 | $0.27 |
| Simonian Nancy ADirector | Nov 25, 2024 | Sell | 134,713 | $0.27 |
| Stephens KristinOfficer — Chief Development Officer | Nov 18, 2024 | Sell | 36,133 | $0.22 |
| Roth DavidOfficer — Chief Medical Officer | Nov 18, 2024 | Sell | 12,099 | $0.20 |
| Quirk Gerald EOfficer — Chief Legal & Compliance Offic | Nov 19, 2024 | Sell | 46,657 | $0.22 |
| Chee ConleyOfficer — President & CEO | Nov 18, 2024 | Sell | 134,797 | $0.20 |
| Haas JasonOfficer — Chief Financial Officer | Nov 18, 2024 | Sell | 137,803 | $0.21 |
| Simonian Nancy ADirector | Oct 31, 2024 | Option exercise | 40,125 | — |
| Roth DavidOfficer — Chief Medical Officer | Oct 31, 2024 | Option exercise | 18,875 | — |
| Haas JasonOfficer — Chief Financial Officer | Oct 31, 2024 | Option exercise | 18,875 | — |
| Chee ConleyOfficer — President & CEO | Oct 31, 2024 | Option exercise | 17,000 | — |
| Stephens KristinOfficer — Chief Development Officer | Oct 31, 2024 | Option exercise | 17,000 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 45,264 | 2.3 | -0.8% |
| Apr 30, 2026 | 45,649 | 5.6 | -2.8% |
| Apr 15, 2026 | 46,984 | 3.0 | -0.7% |
| Mar 31, 2026 | 47,299 | 1.5 | -0.8% |
| Mar 13, 2026 | 47,655 | 1.3 | -0.4% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Other material eventMar 4, 2025
- Delisting / listing-standard notice · Director / officer change · Other material eventFeb 28, 2025
- Delisting / listing-standard noticeJan 8, 2025
- Entered a material agreementDec 6, 2024
- Terminated a material agreement · Debt acceleration / triggering event · Costs from exit or disposal · Director / officer changeNov 18, 2024
- Debt acceleration / triggering event · Other material eventNov 13, 2024
- Regulation FD disclosureSep 5, 2024
- Other material eventAug 12, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.